| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Alkermes plc. | Director | Ordinary Shares | 20,783 | $631,387 | $30.38 | 31 May 2025 | By the Snyderman Trust |
| Alkermes plc. | Director | Non Qualified Stock Option (Right to Buy) | 17,492 | $537,354 | $30.72 | 31 May 2024 | Direct |
| Alkermes plc. | Director | Ordinary Shares | 10,728 | $328,384 | $30.61 | 31 May 2025 | Direct |
| Future Health ESG Corp. | Director | Common stock, par value $0.0001 per share | 11,262 | $134,130 | $11.91 | 24 Oct 2021 | Indirect |
| Future Health ESG Corp. | Director | Common stock, par value $0.0001 per share | 11,250 | $133,988 | $11.91 | 24 Oct 2021 | Direct |
| Axonics, Inc. | Director | Common Stock | 0 | $0 | $71.00 | 15 Nov 2024 | Direct |
| Axonics, Inc. | Director | Stock Option (Right to Buy) | 0 | $0 | $49.96 | 15 Nov 2024 | Direct |
| Lyra Therapeutics, Inc. | Director | Restricted Stock Units | 32,000 | 14 May 2025 | Direct | ||
| Lyra Therapeutics, Inc. | Director | Stock Option | 30,000 | 13 Jun 2024 | Direct | ||
| Alkermes plc. | Director | Non Qualified Stock Option (Right to Buy) | 13,474 | 21 May 2025 | Direct | ||
| Alkermes plc. | Director | Restricted Stock Unit Award | 0 | 31 May 2025 | Direct |